Page:United States Statutes at Large Volume 124.djvu/1000

 124 STAT. 974 PUBLIC LAW 111–148—MAR. 23, 2010 (3) TECHNICAL AND CONFORMING AMENDMENTS.— (A) Section 401(b)(24) of the Public Health Service Act (42 U.S.C. 281(b)(24)) is amended by striking ‘‘Center’’ and inserting ‘‘Institute’’. (B) Subsection (d)(1) of section 903 of the Public Health Service Act (42 U.S.C. 299a–1(d)(1)) is amended by striking ‘‘section 485E’’ and inserting ‘‘section 464z–3’’. SEC. 10335. TECHNICAL CORRECTION TO THE HOSPITAL VALUE-BASED PURCHASING PROGRAM. Section 1886(o)(2)A) of the Social Security Act, as added by section 3001, is amended, in the first sentence, by inserting ‘‘, other than measures of readmissions,’’ after ‘‘shall select measures’’. SEC. 10336. GAO STUDY AND REPORT ON MEDICARE BENEFICIARY ACCESS TO HIGH-QUALITY DIALYSIS SERVICES. (a) STUDY.— (1) IN GENERAL.—The Comptroller General of the United States shall conduct a study on the impact on Medicare bene- ficiary access to high-quality dialysis services of including speci- fied oral drugs that are furnished to such beneficiaries for the treatment of end stage renal disease in the bundled prospec- tive payment system under section 1881(b)(14) of the Social Security Act (42 U.S.C. 1395rr(b)(14)) (pursuant to the proposed rule published by the Secretary of Health and Human Services in the Federal Register on September 29, 2009 (74 Fed. Reg. 49922 et seq.)). Such study shall include an analysis of— (A) the ability of providers of services and renal dialysis facilities to furnish specified oral drugs or arrange for the provision of such drugs; (B) the ability of providers of services and renal dialysis facilities to comply, if necessary, with applicable State laws (such as State pharmacy licensure requirements) in order to furnish specified oral drugs; (C) whether appropriate quality measures exist to safe- guard care for Medicare beneficiaries being furnished speci- fied oral drugs by providers of services and renal dialysis facilities; and (D) other areas determined appropriate by the Comp- troller General. (2) SPECIFIED ORAL DRUG DEFINED.—For purposes of para- graph (1), the term ‘‘specified oral drug’’ means a drug or biological for which there is no injectable equivalent (or other non-oral form of administration). (b) REPORT.—Not later than 1 year after the date of the enact- ment of this Act, the Comptroller General of the United States shall submit to Congress a report containing the results of the study conducted under subsection (a), together with recommenda- tions for such legislation and administrative action as the Comp- troller General determines appropriate. Subtitle D—Provisions Relating to Title IV SEC. 10401. AMENDMENTS TO SUBTITLE A. (a) Section 4001(h)(4) and (5) of this Act is amended by striking ‘‘2010’’ each place such appears and inserting ‘‘2020’’. (b) Section 4002(c) of this Act is amended— 42 USC 300u–11. 42 USC 300u–10. 42 USC 1395ww.